AstraZeneca (AZN)
(Real Time Quote from BATS)
$77.63 USD
+0.07 (0.09%)
Updated Sep 17, 2025 01:14 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, AstraZeneca PLC has a PEG ratio of 1.48 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.65.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AZN 77.63 +0.07(0.09%)
Will AZN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AZN
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer
OLMA Stock Soars 47% in September So Far on Second PFE Deal
Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
Other News for AZN
Trump’s UK Visit Prompts GSK to Commit $30B in U.S. Investment
Brit Pop: HSBC, AZN, ARM – 3 British Stocks Saluted By Our AI Analyst
AstraZeneca's (AZN) Fasenra COPD Trial Misses Key Endpoint
AstraZeneca fails to meet main goal in lung disease trial
AstraZeneca (AZN) Advances Saphnelo Injectable in Key Phase 3 Trial